The cost-efficacy of allergen immunotherapy on Chinese children with moderate to severe rhinitis

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPN-15006592

Enrollment

Unknown

Registered

2015-06-15

Start date

2015-06-19

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic rhinitis

Interventions

Conventionnel HDM Alutard AIT Group :Conventionnel HDM Alutard

Symptomatic allergy medication only group:Symptomatic allergy medication

Eligibility

Sex/Gender

All

Age

5 Years to 14 Years

Inclusion criteria

Inclusion criteria: 1. 5-14 years old Children; 2. SPT HDM Der p or Der f positive (>=2 class); 3. allergic rhinitis with/without asthma symptoms.

Exclusion criteria

Exclusion criteria: No special requirements. Follow the manufacture/s recommendation, product insert and clinical guidelines.

Design outcomes

Primary

Measure	Time frame
Treatment costs on AR;Medications on AR;Rhinitis symptoms;Asthma symptoms;Juniper's RQLQ&AQLQ;Symptom days during treatment;Asthma exacerbation days during treatment;Off-school days due to diseases during treatment;Occurrence of other diseases during treatment;	—

Secondary

Measure	Time frame
IgE, IgG;	—

Countries

China

Contacts

Public ContactChen Jianjun

jj-c@tom.com+86 13659851719

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026